A RETROSPECTIVE, REAL-LIFE EVALUATION OF THE CARDIOVASCULAR DISEASE RISK ASSOCIATED WITH EXPOSURE TO PHARMACOLOGICAL SMOKING CESSATION INTERVENTIONS IN A REPRESENTATIVE UK PRIMARY CARE PATIENT POPULATIONFirst published 02/07/2013 Last updated 02/07/2024 EU PAS number: EUPAS4238StudyFinalised
Respiratory Effectiveness Group (REG)BelgiumDenmarkFranceGermanyGreeceHungaryItalyNetherlandsSpainSwedenUnited Kingdom First published: 07/07/2021Last updated 04/06/2024 NetworkENCePP partner